AML Clinical Trial
Official title:
A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5
Verified date | January 2010 |
Source | Nordic MDS Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Medical Products Agency |
Study type | Interventional |
The aim of this study is to investigate the efficacy of lenalidomide in high risk MDS or AML with chromosome 5 aberrations.
Status | Completed |
Enrollment | 28 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be >18 years of age at the time of signing the informed consent form - MDS at IPSS Int-2 or High with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe) - Acute myeloid leukemia with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe) - Patients could be included if: - At diagnosis and not considered eligible for induction chemotherapy - Refractory to induction therapy - Relapse after induction chemotherapy leading to CR and considered not eligible for reinduction - Relapse after allogeneic stem cell transplantation and not considered suitable for reinduction chemotherapy or other conventional relapse therapy. - Subject has signed the informed consent document. - Women of childbearing potential, WCBP, must agree to practice complete abstinence from heterosexual intercourse or to use two methods of contraception beginning 4 weeks prior to the start of the study medication, while on study medication and 4 weeks after the last dose of study medication. WCBP must have two negative serum or urine pregnancy tests prior to starting study drug. WCBP must agree to have pregnancy tests weekly for the first 4 weeks and then every 4 weeks while on study medication and 4 weeks after the last dose of study medication. - Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on study medication and 4 weeks after the last dose of study medication. Exclusion Criteria: - Pregnant or lactating females. - Prior therapy with lenalidomide - Patients who are eligible for curative treatment - Expected survival less than two months. - Acute promyelocytic leukemia (APL) - Absolute peripheral blast count >30,000/mm3 - Central nervous system leukemia - Serum biochemical values as follows - Serum creatinine >2.0 mg/dL (177 micromol/L) - Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) >3.0 x upper limit of normal (ULN) - Serum total bilirubin >1.5 mg/dL (26 micromol/L) - Prior allergic reaction to thalidomide - Uncontrolled systemic infection |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Hematology, Aalborg Hospital | Aalborg | |
Denmark | Department of Hematology, Aarhus University Hospital | Aarhus | |
Denmark | Department of Hematology, Rigshospitalet | Copenhagen | |
Denmark | Department of Hematology, Herlev Hospital | Herlev | |
Denmark | Department of Hematology, Odense University Hospital | Odense | |
Denmark | Department of Hematology, Vejle Hospital | Vejle | |
Norway | Department of Hematology, Rikshospitalet University Hospital | Oslo | |
Norway | Department of Medicine, Ullevål Hospital | Oslo | |
Norway | Department of Hematology, Trondheim University Hospital | Trondheim | |
Sweden | Department of Hematology and Coagulation, Sahlgrenska University hospital | Gothenburg | |
Sweden | Department of Hematology, Lund University Hospital | Lund | |
Sweden | Department of Hematology, Malmö University Hospital | Malmö | |
Sweden | Department of Medicine, Örebro University Hospital | Örebro | |
Sweden | Hematology Center, Karolinska University Hospital Huddinge | Stockholm | |
Sweden | Hematology Center, Karolinska University Hospital Solna | Stockholm | |
Sweden | Department of Medicine, Sundsvall Hospital | Sundsvall | |
Sweden | Department of Medicine, Umeå University Hospital | Umeå | |
Sweden | Department of Hematology, Akademiska University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Nordic MDS Group |
Denmark, Norway, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major cytogenetic response (50% or more reduction of the del5(q) or monosomy 5 FISH positive clone in the bone marrow using the LSI EGR1/D5S23,D5S721 FISH probe) after 16 weeks of lenalidomide treatment | 16 weeks | No | |
Secondary | Minor and complete cytogenetic (FISH) response after 8 and 16 weeks | 16 weeks | No | |
Secondary | Red blood cell transfusion independence | 16 weeks | No | |
Secondary | Erythroid response | 16 weeks | No | |
Secondary | Bone marrow response (morphology) | 16 weeks | No | |
Secondary | Modification of gene expression profiling during treatment | 16 weeks | No | |
Secondary | Safety | 16 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03118466 -
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
Withdrawn |
NCT03444649 -
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
|
Phase 1 | |
Withdrawn |
NCT02905994 -
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT02261779 -
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
|
Phase 1/Phase 2 | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Completed |
NCT00246649 -
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia
|
N/A | |
Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Terminated |
NCT01570465 -
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
|
||
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 | |
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Completed |
NCT02575963 -
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00780598 -
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
|
Phase 2 | |
Completed |
NCT00542971 -
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
|
Phase 1/Phase 2 | |
Completed |
NCT00589082 -
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
|
Phase 3 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A |